This retrospective cohort study assessed the impact of body mass index (BMI) variation on recurrence risk in women with early-stage breast cancer. The analysis revealed that a BMI increase exceeding 5.71% post-diagnosis was significantly associated with higher recurrence rates. Additional factors linked to increased recurrence included age under 55 years,
This 1999 study evaluated the safety of estrogen replacement therapy (ERT) in 76 women with a history of breast cancer, including 50 who used ERT for up to 32 years. The findings indicated that ERT did not increase the risk of cancer recurrence or mortality. Additionally, the addition of progestogens
This meta-analysis and expert panel discussion evaluated the safety of topical estrogen (TE) therapy in breast cancer survivors undergoing adjuvant endocrine treatment with tamoxifen (TAM) or aromatase inhibitors (AIs). Analyzing six observational studies with 38,050 patients, including 1,805 exposed to TE, the study found that TE use with TAM did
